Put companies on watchlist
MediClin AG
ISIN: DE0006595101
WKN: 659510
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

MediClin AG · ISIN: DE0006595101 · EQS - Company News (52 News)
Country: Germany · Primary market: Germany · EQS NID: 1570907
28 February 2023 02:00PM

MediClin AG: Disclosure of the preliminary figures of the 2022 financial year


EQS-News: MediClin AG / Key word(s): Preliminary Results
MediClin AG: Disclosure of the preliminary figures of the 2022 financial year

28.02.2023 / 14:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


Offenburg, 26 February 2023

Disclosure of the preliminary figures of the 2022 financial year

In the 2022 financial year MEDICLIN achieved Group sales in the amount of EUR 704.7 mill. (previous year: EUR 673.1 mill.) and a Group operating result of EUR 19.5 mill. (previous year: E§UR 11.6 mill.). As a result, both Group sales and Group operating result were within the corridor of the forecast published for the year 2022.

As far as Group operating result is concerned, higher sales revenues and lower depreciation and amortization of rights of use contributed to the improvement in earnings. The result was impacted by energy costs and one-off costs in connection with the closure of a post-acute care clinic.

Sales increase in the segments and the nursing care business area

In the post-acute (rehabilitation) segment, revenues of EUR 431.2 mill. were EUR 20.4 mill. or 5.0% above the comparative figure of the previous year. Sales of the acute segment of EUR 252.7 mill. increased by EUR 9.3 mill. or 3.8% compared to the previous year. Sales in the nursing care business area rose to EUR 18.7 mill. in the year under review (previous year: EUR 17.3 mill.).

As far as segment results are concerned, the post-acute segment achieved a result of EUR 21.2 mill. (previous year: EUR 15.3 million). With a loss of EUR 4.4 million, the acute segment was slightly above the previous year's figure (previous year: EUR -4.0 million).

Staff and investments

The number of employees was 9,959 on December 31, 2022. Calculated in full-time equivalents, the average number in the reporting year 2022 was 7,025 full-time employees (previous year: 7,115 full-time employees). In 2022, gross investments in fixed assets amounted to EUR 28.5 mill. (previous year: EUR 18.1 mill.).

The Annual Report 2022 will be available from 31 March 2023 under www.mediclin.de in German and English.

 

About MEDICLIN Aktiengesellschaft (Ticker: MED; WKN: 659 510)

MEDICLIN includes 35 clinics, seven care facilities and eleven medical care centers. The Group has around 8,300 beds/care places and employs around 10,000 people. In a strong network, MEDICLIN offers the patient integrative care from the first visit to the doctor through the operation and subsequent rehabilitation to outpatient aftercare. Doctors, therapists and nurses work together in a carefully coordinated manner. MEDICLIN designs the care and support of people in need of care according to their individual needs and personal needs.

MEDICLIN ─ a company of the Asklepios Group.

 



28.02.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: MediClin AG
Okenstraße 27
77652 Offenburg
Germany
Phone: +49 (0)781 488-326
Fax: +49 (0)781 488-184
E-mail: alexandra.muehr@mediclin.de
Internet: www.mediclin.de
ISIN: DE0006595101
WKN: 659510
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1570907

 
End of News EQS News Service

1570907  28.02.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1570907&application_name=news&site_id=boersengefluester_html
Visual performance / price development - MediClin AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.